Traceable Claims in Genomics

Concise Protocol Pack — 4 modular pipelines (click to deep-dive buttons below)

1. Design & in silico QC — target selection, sgRNA design, off-target prediction, donor template planning, and risk assessment using empirical off-target nomination (UNCOVERseq) as benchmark; see citation below for UNCOVERseq method and limitations.
2. DNA/oligo synthesis & QC — apply guanine-debranching step for photolithographic arrays to avoid O6-guanine branching and improve amplifiability; sequence-verify libraries and qPCR-check yields as in the photolithography study.
3. Delivery & editing — choose ex vivo RNP/HSPC workflows for hematologic diseases (higher translational maturity) vs in vivo AAV/LNP/VLP for systemic tissues (muscle) while applying DSB-free editors where possible to reduce genotoxicity; consider CRISPR-VLP for embryo/GEMM generation where applicable.
4. Validation & safety follow-up — combine sensitive nomination (UNCOVERseq or comparable empirical assays), deep amplicon/long-read sequencing, chromosomal structural assays, and long-term functional readouts (in vitro/in vivo) to assess on-/off-targets and structural variants.

Actionable protocol snapshots (copyable checklist)

1) sgRNA & design QC (ex vivo-first strategy)

• Prioritize ex vivo HSPC workflows for blood disorders (mature translational path; clinical trials listed) and use DSB-free editors when feasible to reduce genotoxicity risks CRISPR gene-therapy review
• Use empirical nomination assays (UNCOVERseq) to generate high-sensitivity off-target candidate lists before deep sequencing confirmation; UNCOVERseq reports superior nomination across DSB/SSB modalities in cell models but needs broader clinical validation UNCOVERseq off-target nomination

2) DNA synthesis & oligo library QC

• For photolithographic oligonucleotide libraries, incorporate a brief guanine debranching/capping step (Tac2O / N-methylimidazole step between coupling and drying) to prevent O6-guanine phosphitylation–induced branching and fragmentation; this produced ~6-fold higher hybridization signals and massively improved amplifiability in large arrays Photolithography debranching protocol
• Always sequence-verify complex pools (NGS) and include qPCR DeltaCq controls; the cited study reported ΔCq ~7.84 between debranched and no-debranch libraries, indicating large differences in amplifiable yield.

3) Delivery & editing choices

• Match editing modality to biology: ex vivo RNP electroporation (HSPC, CAR-T) for controlled dosing and transient Cas exposure; AAV/LNP for in vivo (muscle, retina) only after rigorous immunogenicity and dose-escalation studies; VLP-delivered RNPs provide high embryo/zygote editing efficiency for model creation per recent CRISPR-VLP/CRISPR-VIM reports CRISPR-VLP GEMM method
• Prefer DSB-free modalities (ABE/CBE/prime/PASTE) where the target and biology permit—reviews show base/prime editors reduce DSB-associated genotoxicity and are advancing to early clinical use in hematologic contexts Base editing clinical review

4) Validation, safety assays, and longitudinal follow-up

• Combine empirical nomination (UNCOVERseq), targeted deep sequencing (amplicon + capture), structural variant detection (long-read sequencing, optical mapping as available), and functional assays (protein expression, cell function, in vivo phenotypes) before clinical translation; long-term surveillance is essential due to DSB-associated events and potential chromothripsis described in the literature CRISPR therapy safety concerns

• Many recommendations rely on preclinical/early clinical data—animal models and in vitro systems may not fully predict human in vivo outcomes; long-term safety data remain limited Translational limitations review
• Photolithography improvements were shown on a single platform (MAS 2.0); generalizability to other synthesizers should be validated experimentally Debranching platform caveat

Key evidence (selected):

• CRISPR gene-therapy review
• Photolithography debranching protocol
• UNCOVERseq off-target nomination
• CRISPR-VLP GEMM method